Overview

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Bausch Health Americas, Inc.
Treatments:
Antibodies, Monoclonal
Brodalumab
Ustekinumab